top of page
  • Writer's pictureKeith Ward

Kuria Therapeutics to Present at 2023 Ophthalmology Futures Retina Forum

- Kuria's Chief Executive Officer Dr. Keith Ward to discuss preclinical proof-of-concept data in dry AMD and Kuria's development plans

September 20, 2023 Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, has been selected for participation in the Ophthalmology Futures Retina Forum in Amsterdam. Kuria's Chief Executive Officer, Dr. Keith Ward, will appear via a recorded presentation to share Kuria's mission to Power Sight and our development progress for our program in age-related macular degeneration. Dr. Ward's presentation will occur on Wednesday, 04 October 2023 at the meeting in the Hyatt Regency Hotel in Amsterdam, and will also be made available on the Kuria website.

Watch the presentation below

About Kuria Therapeutics, Inc.: Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit

Contacts Investor Relations and Media Kuria Therapeutics: Corporate Communication


Commenting has been turned off.
bottom of page